Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin

Journal of Molecular Biology

Volumn 350, Issue 3, 2005, Pages 416-426

  Murakami, Mário T ^a   Arruda, Emerson Z ^b   Melo, Paulo A ^b   Martinez, Ana B ^b   Calil Eliás, Sabrińa ^b   Tomaz, Marcelo A ^b   Lomonte, Bruno ^c   Gutiérrez, José M ^c   Arni, Raghuvir K ^a,d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^d INSTITUTO BUTANTAN   (Brazil)

Author keywords

Crystal structure; Heparin; Inhibition; Myotoxicity; Suramin

Indexed keywords

HEPARIN; SNAKE VENOM; SURAMIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE;

BOTHROPS ASPER; VIPERIDAE;

EID: 20444450643     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2005.04.072     Document Type: Article

References (59)

1. T.A. Burch, and L.L. Ashburn Experimental therapy of onchocerciasis with suramin and hetrazan; results of a three-year study Am. J. Trop. Med. Hyg. 31 1951 617 623
2. J. Williamson, and R.S. Desowitz Prophylactic activity of suramin complexes in animal trypanosomiasis Nature 177 1956 1074 1075
3. J.K. Cherry The treatment of onchocerciasis East. Afr. Med. J. 37 1960 550 558
4. J. Schneider Treatment of human African trypanosomiasis Bull. World Health Organ. 28 1963 763 786
5. R.V. LaRocca, M.R. Cooper, M. Uhrich, R. Danesi, M.M. Walther, W.M. Linehan, and C.E. Myers Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation Urol. Clin. North Am. 18 1991 123 129
6. A.T. van Oosterom, W.W. ten Bokkel Huinink, M.E. van der Burg, J.B. Vermorken, P.H. Willemse, and J.P. Neijt Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer Eur. J. Cancer 27 1991 747 749
7. J. Waltenberger, U. Mayr, H. Frank, and V. Hombach Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action J. Mol. Cell Cardiol. 28 1996 1523 1529
8. M. Cadene, J. Duranton, A. North, M. Si-Tahar, M. Chignard, and J.G. Bieth Inhibition of neutrophil serine proteinases by suramin J. Biol. Chem. 272 1997 9950 9955
9. P.A. Raj, E. Marcus, and R. Rein Conformational requirements of suramin to target angiogenic growth factors Angiogenesis 2 1998 183 199
10. J.M. Hermans, D.S. Haines, P.S. James, and R. Jones Kinetics of inhibition of sperm beta-acrosin activity by suramin FEBS Letters 544 2003 119 222
11. F.W. Jennings, J. Rodgers, B. Bradley, G. Gettinby, P.G. Kennedy, and M. Murray Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen Parasitol. Int. 51 2002 381 388
12. S.L. Fleck, B. Birdsall, J. Babon, A.R. Dluzewski, S.R. Martin, and W.D. Morgan Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum J. Biol. Chem. 278 2003 47670 47677
13. D.F. McCain, L. Wu, P. Nickel, M.U. Kassack, A. Kreimeyer, and A. Gagliardi Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases J. Biol. Chem. 279 2004 14713 14725
14. C. Fernandez-Tornero, R.M. Lozano, M. Redondo-Horcajo, A.M. Gomez, J.C. Lopez, and E. Quesada Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate J. Biol. Chem. 278 2003 21774 21781
15. E.Z. Arruda, N.M. Silva, R.A. Moraes, and P.A. Melo Effect of suramin on myotoxicity of some crotalid snake venoms Braz. J. Med. Biol. Res. 35 2002 723 726
16. M. de Oliveira, W.L. Cavalcante, E.Z. Arruda, P.A. Melo, M. Dal-Pai Silva, and M. Gallacci Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin Toxicon 42 2003 373 379
17. R.K. Arni, and R.J. Ward Phospholipase A2 - a structural review Toxicon 34 1996 827 841
18. R.M. Kini Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes Toxicon 42 2003 827 840
19. D. Mebs, and C.L. Ownby Myotoxic components of snake venoms: their biochemical and biological activities Pharm. Ther. 48 1990 223 236
20. M.T. da Silva Giotto, R.C. Garratt, G. Oliva, Y.P. Mascarenhas, J.R. Giglio, and A.C. Cintra Crystallographic and spectroscopic characterization of a molecular hinge: conformational changes in bothropstoxin I, a dimeric Lys49-phospholipase A2 homologue Proteins: Struct. Funct. Genet. 30 1998 442 454
21. P.A. Melo, M.C. Nascimento, W.B. Mors, and C.L. Ownby Inhibition of the myotoxic and hemorrhagic activities of crotalid venoms by Eclipta prostrata (Asteraceae) extracts and constituents Toxicon 32 1994 595 603
22. D.L. Scott, Z. Otwinowski, M.H. Gelb, and P.B. Sigler Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue Science 250 1990 1563 1566
23. M.T. Murakami, and R.K. Arni A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A2s Toxicon 42 2003 903 913
24. R.K. Arni, R.J. Ward, J.M. Gutierrez, and A. Tulinsky Structure of a calcium-independent phospholipase-like myotoxic protein from Bothrops asper venom Acta Crystallog. sect. D 51 1995 311 317
25. A.L. Ambrosio, M.C. Nonato, H.S. Selistre-de-Araujo, R.K. Arni, R.J. Ward, and C.L. Ownby A molecular mechanism for Lys49-phospholipase A2 activity based on ligand-induced conformational change J. Biol. Chem. 280 2005 7326 7335
26. L. Watanabe, A.M. Soares, R.J. Ward, M.R.M. Fontes, and R.K. Arni Structural insights for fatty acid binding in a Lys49-phospholipase A(2): crystal structure of myotoxin II from Bothrops moojeni complexed with stearic acid Biochimie 87 2005 161 167
27. W.H. Lee, M.T. da Silva Giotto, S. Marangoni, M. Toyama, I. Polikarpov, and R.C. Garrat Structural basis for low catalytic activity in Lys49 phospholipases A2 - a hypothesis: the crystal structure of piratoxin II complexed to fatty acid Biochemistry 40 2001 28 36
28. B. Lomonte, Y. Angulo, and C. Santamarǐa Comparative study of synthetic peptides corresponding to region 115-129 in Lys49 myotoxic phospholipases A2 from snake venoms Toxicon 42 2003 307 312
29. B. Lomonte, Y. Angulo, and L. Calderǒn An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action Toxicon 42 2003 885 901
30. R.J. Ward, L. Chioato, A.H. de Oliveira, R. Ruller, and J.M. Sa Active-site mutagenesis of a Lys49-phospholipase A2: biological and membrane-disrupting activities in the absence of catalysis Biochem. J. 362 2002 89 96
31. P.A. Melo, and G. Suarez-Kurtz Release of creatine kinase from skeletal muscles by Bothrops venoms: heparin potentiation of inhibition by antivenin Braz. J. Med. Biol. Res. 21 1988 548 558
32. P.A. Melo, and G. Suarez-Kurtz Release of sarcoplasmic enzymes from skeletal muscle by Bothrops jararacussu venom: antagonism by heparin and by the serum of South American marsupials Toxicon 26 1988 87 95
33. B. Lomonte, A. Tarkowski, U. Bagge, and L.A. Hanson Neutralization of the cytolytic and myotoxic activities of phospholipases A2 from Bothrops asper snake venom by glycosaminoglycans of the heparin/heparan sulfate family Biochem. Pharmacol. 47 1994 1509 1518
34. B. Lomonte, E. Moreno, A. Tarkowski, L.A. Hanson, and M. Maccarana Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling J. Biol. Chem. 269 1994 29867 29873
35. P.A. Melo, M.I. Homsi-Brandeburgo, J.R. Giglio, and G. Suarez-Kurtz Antagonism of the myotoxic effects of Bothrops jararacussu venom and bothropstoxin by polyanions Toxicon 31 1993 285 291
36. I. Krizaj, D. Turk, A. Ritonja, and F. Gubensek Primary structure of ammodytoxin C further reveals the toxic site of ammodytoxin Biochim. Biophys. Acta 999 1989 198 202
37. H.S. Selistre de Araujo, S.P. White, and C.L. Ownby Sequence analysis of Lys49 phospholipase A2 myotoxins: a highly conserved class of proteins Arch. Biochem. Biophys. 326 1996 21 30
38. R.J. Ward, A. Rodrigues Alves, J. Rugierro Neto, R.K. Arni, and J.A. Casari Sequence space analysis of Lys49 phopholipases A2: clues towards identification of residues involved in a novel mechanism of membrane damage and in myotoxicity Protein Eng. 11 1998 285 294
39. R.M. Kini, and S. Iwanaga Structure-function relationships of phospholipases. II: charge density distribution and the myotoxicity of presynaptically neurotoxic phospholipases Toxicon 24 1986 895 905
40. R.M. Kini, and H.J. Evans Role of cationic residues in cytolytic activity: modification of lysine residues in the cardiotoxin from Naja nigricollis venom and correlation between cytolytic and antiplatelet activity Biochemistry 28 1989 9209 9216
41. M. Falconi, A. Desideri, and S. Rufini Membrane-perturbing activity of Viperidae myotoxins: an electrostatic surface potential approach to a puzzling problem J. Mol. Recogn. 13 2000 14 19
42. S.H. Andrião-Escarso, A.M. Soares, V.M. Rodrigues, Y. Angulo, C. Dǐaz, and B. Lomonte Myotoxic phospholipases A(2) in Bothrops snake venoms: effect of chemical modifications on the enzymatic and pharmacological properties of bothropstoxins from Bothrops jararacussu Biochimie 82 2000 755 763
43. A.M. Soares, S.H. Andrião-Escarso, R.K. Bortoleto, L. Rodrigues-Simioni, R.K. Arni, and R.J. Ward Dissociation of enzymatic and pharmacological properties of piratoxins-I and -III, two myotoxic phospholipases A2 from Bothrops pirajai snake venom Arch. Biochem. Biophys. 387 2001 188 196
44. L. Calderǒn, and B. Lomonte Immunochemical characterization and role in toxic activities of region 115-129 of myotoxin II, a Lys49 phospholipase A2 from Bothrops asper snake venom Arch. Biochem. Biophys. 358 1998 343 350
45. C.E. Nǔñez, Y. Angulo, and B. Lomonte Identification of the myotoxic site of the Lys49 phospholipase A(2) from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities Toxicon 39 2001 1587 1594
46. L. Chioato, A.H.C. Oliveira, R. Ruller, J.M. Sǎ, and R.J. Ward Distinct sites for myotoxic and membrane-damaging activities in the C-terminal region of a Lys49-phospholipase A2 Biochem. J. 366 2002 971 976
47. C. Fernandez-Tornero, R.M. Lozano, M. Redondo-Horcajo, A.M. Gomez, J.C. Lopez, and E. Quesada Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate J. Biol. Chem. 278 2003 21774 21781
48. L. Pǎramo, B. Lomonte, J. Pizarro-Cerdǎ, J.A. Bengoechea, J.P. Gorvel, and E. Moreno Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from Bothrops asper snake venom-synthetic Lys49 myotoxin II-(115-129)-peptide identifies its bactericidal region Eur. J. Biochem. 253 1998 452 461
49. 2 Enzymes: Structure, Function and Mechanism 1997 Wiley Chichester 321
50. W.H. Lee, M.H. Toyama, A.M. Soares, J.R. Giglio, S. Marangoni, and I. Polikarpov Crystallization and preliminary X-ray diffraction studies of piratoxin III, a D-49 phospholipase A2 from the venom of Bothrops pirajai Acta Crystallog. sect. D 55 1999 1229 1230
51. B. Lomonte, and J.M. Gutiěrrez A new muscle damaging toxin, myotoxin II, from the venom of the snake Bothrops asper (terciopelo) Toxicon 27 1989 725 733
52. J. Mass, W. Heling, and K. Seeger Anesthesia of experimental animals H.G. Vogel W. Vogel Drug Discovery and Evaluation: Pharmacological Assays 1997 Spring-Verlag Berlin 732
53. P.A. Melo, and C.L. Ownby Ability of wedelolactone, heparin, and para-bromophenacyl bromide to antagonize the myotoxic effects of two crotaline venoms and their PLA2 myotoxins Toxicon 37 1999 199 192
54. M.T. Murakami, L.M. Gava, S.P. Zela, E.Z. Arruda, P.A. Melo, J.M. Gutierrez, and R.K. Arni Crystallization and preliminary X-ray diffraction analysis of suramin, a highly charged polysulfonated napthylurea, complexed with a myotoxic PLA2 from Bothrops asper venom Biochim. Biophys. Acta 1703 2004 83 85
55. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collection in oscillation mode Methods Enzymol. 276 1997 307 326
56. J. Navaza AMoRe: an automated package for molecular replacement Acta Crystallog. sect. A 50 1994 157 163
57. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallog. sect. D 53 1997 240 255
58. A. Roussel, and C. Cambillau Turbo-Frodo Silicon Graphics Silicon Graphics Geometry Partner Directory 1989 Mountain View CA 77
59. R.A. Laskowski, M.W. MacArthur, D.S. Moss, and J.M. Thornton PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallog. 26 1993 283 291